Jefferies on Corbus Pharmaceuticals (CRBP): FDA alignment de-risks, focus shifts to efficacy

April 7, 2026 2:49 PM

Jefferies analyst Maury Raycroft reiterated a Buy rating and $36.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP)The analyst commented, "CRBP’s ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found